The Definitive Study On Zantac Cancer May Be To Test a Patient's Urine Immediately After Taking The Antacid

A simple way to see if Zantac ranitidine becomes carcinogenic is to perform before and after urine tests

Tuesday, August 17, 2021 - Controversy surrounds Zantac ranitidine and whether or not it causes cancer. Some think it does and some think it does not. Until today I had not read any study that would provide definitive evidence that ranitidine is so unstable that it breaks down to form carcinogenic N-nitrosodimethylamine (NDMA) when it is exposed to the increased temperatures inside the human body as online prescription drug testing pharmacy Valisure claims. Critics of Valisure's findings of NDMA levels as high as 3 million nanograms per ranitidine tablet say that the pharmacy's high-heat testing method caused the NDMA spike. That said, thousands of individuals with stomach, bladder, esophagus, colon, prostate, and other forms of cancer have registered with a Zantac cancer attorney to file a claim seeking lump-sum monetary damages having taken Zantac regularly for several years or longer.

As recently as June 21, 2021, internet medical experts at WebMd.com addressed this question and came up with some interesting opinions. The online medical experts cite research that seems to confirm Valisure's elevated NDMA counts, citing a study that shows that NDMA levels in patient's urine increased four-fold after taking a prescribed dosage of Zantac ranitidine. According to WMD, "healthy men and women who took a normal dose of the heartburn medicine ranitidine, often known by the brand name Zantac, had extremely high levels of a chemical known as NDMA, a probable cancer-causing substance. NDMA levels in their urine increased by 400-fold after taking a dose of the antacid, the researchers found." The US Food and Drug Administration has set a limit of 96 nanograms per tablet as the daily safe amount of NDMA.

Whether or not Zantac ranitidine is overheated and becomes carcinogenic during the manufacturing process, transportation, storage, or within the body is a moot point from a legal standpoint. Many Zantac cancer questions need answers, and Zantac cancer lawsuits will assert that Sanofi, the most recent Zantac patent holder and manufacturer, and also others either knew or had a responsibility to know that NDMA levels were increasing given the simple before and after urine tests that could have been performed. So certain is Sanofi's culpability that the US Department of Justice has accused the company of lying to the FDA about their knowledge of ranitidine degrading to form NDMA, and a formal investigation is ongoing. It also appears that chemistry supports Valisure's claim that ranitidine is a fundamentally unstable molecule, and turns into NDMA with only the slightest modification. "The ranitidine molecule itself is fundamentally unstable," says David Light, CEO of Valisure, an online pharmacy, and testing laboratory. The ranitidine molecule itself is fundamentally unstable," says David Light, CEO of Valisure, an online pharmacy, and testing laboratory," according to WMD. Federal court proceedings will begin in September 2021, when a judge has scheduled Daubert hearings to interview potential expert witnesses from both sides and determine which scientific testimony to allow juries to hear.">

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.